Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells
暂无分享,去创建一个
K. Anderson | P. Richardson | D. Chauhan | N. Raje | A. Ray | Madhavi L. Bandi | Ajita V. Singh | K. Anderson | Madhavi Bandi | K. Anderson
[1] J. Kyriakis. Faculty Opinions recommendation of SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. , 2010 .
[2] David P. Carney,et al. SIRT1 Activation by Small Molecules , 2010, The Journal of Biological Chemistry.
[3] J. Friedberg,et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. , 2010, Blood.
[4] R. Schnellmann,et al. SRT1720 Induces Mitochondrial Biogenesis and Rescues Mitochondrial Function after Oxidant Injury in Renal Proximal Tubule Cells , 2010, Journal of Pharmacology and Experimental Therapeutics.
[5] P. Richardson,et al. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. , 2010, Blood.
[6] D. Sinclair,et al. Mammalian sirtuins: biological insights and disease relevance. , 2010, Annual review of pathology.
[7] Venkataraman Thanabal,et al. SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1♦ , 2010, The Journal of Biological Chemistry.
[8] G. Leone,et al. Division and apoptosis of E2f-deficient retinal progenitors , 2009, Nature.
[9] L. Gordon,et al. PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells , 2009, Clinical Cancer Research.
[10] T. Yeatman,et al. SirT1 Is an Inhibitor of Proliferation and Tumor Formation in Colon Cancer* , 2009, The Journal of Biological Chemistry.
[11] A. Sauve,et al. Pharmaceutical strategies for activating sirtuins. , 2009, Current pharmaceutical design.
[12] J. Olefsky,et al. SIRT1 Exerts Anti-Inflammatory Effects and Improves Insulin Sensitivity in Adipocytes , 2008, Molecular and Cellular Biology.
[13] X. Wang,et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. , 2008, Cancer cell.
[14] W. Hahn,et al. The SIRT1 Deacetylase Suppresses Intestinal Tumorigenesis and Colon Cancer Growth , 2008, PloS one.
[15] J. Denu,et al. The Sirtuin family: therapeutic targets to treat diseases of aging. , 2008, Current opinion in chemical biology.
[16] P. Dent,et al. Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells , 2008, Clinical Cancer Research.
[17] Irving L Weissman,et al. SIRT1 acts as a nutrient-sensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity. , 2007, Molecular biology of the cell.
[18] N. Munshi,et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. , 2007, Blood.
[19] E. Seto,et al. A Functional Link Between SIRT1 Deacetylase and NBS1 in DNA Damage Response , 2007, Cell cycle.
[20] M. Salto‐Tellez,et al. Function of the SIRT1 protein deacetylase in cancer. , 2007, Biotechnology journal.
[21] Jun Wang,et al. Resveratrol Suppresses Prostate Cancer Progression in Transgenic Mice , 2007 .
[22] Kenneth C. Anderson,et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.
[23] R. Bataille,et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.
[24] B. Aggarwal,et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. , 2007, Blood.
[25] Kotb Abdelmohsen,et al. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. , 2007, Molecular cell.
[26] K. Anderson,et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. , 2006, Blood.
[27] E. Asselin,et al. Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells , 2006, Molecular Cancer.
[28] N. Pattabiraman,et al. Hormonal Control of Androgen Receptor Function through SIRT1 , 2006, Molecular and Cellular Biology.
[29] R. DePinho,et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. , 2006, Cancer research.
[30] C. Kamel,et al. SirT1 fails to affect p53‐mediated biological functions , 2006, Aging cell.
[31] Y. Ouchi,et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras–MAPK signaling in human cancer cells , 2006, Oncogene.
[32] P. Distefano,et al. Inhibition of SIRT1 Catalytic Activity Increases p53 Acetylation but Does Not Alter Cell Survival following DNA Damage , 2006, Molecular and Cellular Biology.
[33] J. Milner,et al. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. , 2005, Cancer research.
[34] P. L. Bergsagel,et al. Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Michael M. Murphy,et al. Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. , 2005, Cell metabolism.
[36] S. Schreiber,et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[37] M. Mayo,et al. Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase , 2004, The EMBO journal.
[38] Gonzalez,et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. , 2003, Blood.
[39] R. Fonseca,et al. Expression of VEGF and its receptors by myeloma cells , 2003, Leukemia.
[40] D. Chauhan,et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. , 2003, Experimental hematology.
[41] D. Neuberg,et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. , 2002, Cancer research.
[42] J. Denu,et al. Structural Identification of 2′- and 3′-O-Acetyl-ADP-ribose as Novel Metabolites Derived from the Sir2 Family of β-NAD+-dependent Histone/Protein Deacetylases* 210 , 2002, The Journal of Biological Chemistry.
[43] N. Munshi,et al. NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.
[44] J. Denu,et al. Conserved Enzymatic Production and Biological Effect of O-Acetyl-ADP-ribose by Silent Information Regulator 2-like NAD+-dependent Deacetylases* , 2002, The Journal of Biological Chemistry.
[45] Kenneth C. Anderson,et al. Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with β1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCα Activation* , 2002, The Journal of Biological Chemistry.
[46] N. Munshi,et al. NF-kappa B as a therapeutic target in multiple myeloma. , 2002, The Journal of biological chemistry.
[47] K. Anderson,et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. , 2001, Blood.
[48] H. Steininger,et al. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. , 2001, The hematology journal : the official journal of the European Haematology Association.
[49] G Muller,et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. , 2000, Blood.
[50] S. Rajkumar,et al. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. , 2000, Cancer treatment reviews.
[51] L. Guarente,et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase , 2000, Nature.
[52] A. Strasser,et al. Apoptosis signaling. , 2000, Annual review of biochemistry.
[53] L K Miller,et al. An exegesis of IAPs: salvation and surprises from BIR motifs. , 1999, Trends in cell biology.
[54] D. Green,et al. Apoptosis: checkpoint at the mitochondrial frontier. , 1999, Mutation research.
[55] D. Ribatti,et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. , 1999, Blood.
[56] P. L. Bergsagel,et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[57] T. Libermann,et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. , 1996, Blood.
[58] Y. Lazebnik,et al. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE , 1994, Nature.
[59] R. A. Singer,et al. Transcriptional Silencing , 2022 .
[60] R. Huber,et al. Transcriptional silencing and longevity protein Sir 2 is an NAD-dependent histone deacetylase , 2022 .